Journal of Clinical Endocrinology & Metabolism, Vol 78, 842-846, Copyright © 1994 by Endocrine Society

ARTICLES

H-ras mutations in human pituitary carcinoma metastases

L Pei, S Melmed, B Scheithauer, K Kovacs and D Prager
Department of Medicine, Cedars-Sinai Medical Center-UCLA School of Medicine 90048.

Molecular mechanisms of pituitary tumorigenesis were studied using Polymerase chain reaction-single stranded conformational polymorphism with DNA sequencing to identify potential mutations in the ras protooncogenes and the tumor suppressor gene p53 in invasive pituitary adenomas and carcinomas. Sequencing of exons 5 through 8 of the p53 gene revealed no mutations, nor were mutations detected in the N- or K- ras protooncogenes in four of the carcinomas and their respective metastatic deposits. Point mutations of H-ras however, were identified in three distant metastatic pituitary tumor secondaries, but not in their respective primary pituitary carcinomas, or in six invasive adenomas. Two of the mutations included a G to C substitution at codon 12, and a G to A substitution at codon 18, resulting in a glycine to arginine, and an alanine to threonine change at these amino acids, respectively. A third mutation involved a single base pair (adenine) deletion in codon 3 of H-ras which causes a frame shift, resulting in a termination signal at codon 19. These results suggest that point mutations in p53 and ras are not associated with pituitary tumorigenesis, however, point mutations of the H-ras gene may be important in the formation and or growth of pituitary metastases. This observed genomic instability will be of value in predicting the potential metastatic behavior of these aggressive pituitary tumors.

This article has been cited by other articles:

				A. Wierinckx, C. Auger, P. Devauchelle, A. Reynaud, P. Chevallier, M. Jan, G. Perrin, M. Fevre-Montange, C. Rey, D. Figarella-Branger, et al. A diagnostic marker set for invasion, proliferation, and aggressiveness of prolactin pituitary tumors Endocr. Relat. Cancer, September 1, 2007; 14(3): 887 - 900. [Abstract] [Full Text] [PDF]

				M. P. Gillam, M. E. Molitch, G. Lombardi, and A. Colao Advances in the Treatment of Prolactinomas Endocr. Rev., August 1, 2006; 27(5): 485 - 534. [Abstract] [Full Text] [PDF]

				G. A. Kaltsas, P. Nomikos, G. Kontogeorgos, M. Buchfelder, and A. B. Grossman Diagnosis and Management of Pituitary Carcinomas J. Clin. Endocrinol. Metab., May 1, 2005; 90(5): 3089 - 3099. [Abstract] [Full Text] [PDF]

				M. Facchetti, D. Uberti, M. Memo, and C. Missale Nerve Growth Factor Restores p53 Function in Pituitary Tumor Cell Lines via trkA-Mediated Activation of Phosphatidylinositol 3-Kinase Mol. Endocrinol., January 1, 2004; 18(1): 162 - 172. [Abstract] [Full Text] [PDF]

				A. Lania, G. Mantovani, and A. Spada Genetics of Pituitary Tumors: Focus on G-Protein Mutations Experimental Biology and Medicine, October 1, 2003; 228(9): 1004 - 1017. [Abstract] [Full Text] [PDF]

				J W Ironside Best Practice No 172: Pituitary gland pathology J. Clin. Pathol., August 1, 2003; 56(8): 561 - 568. [Abstract] [Full Text] [PDF]

				B. Xu, T. Sano, S. Yamada, C. C. Li, and M. Hirokawa Expression of Corticotropin-Releasing Hormone Messenger Ribonucleic Acid in Human Pituitary Corticotroph Adenomas Associated with Proliferative Potential J. Clin. Endocrinol. Metab., March 1, 2000; 85(3): 1220 - 1225. [Abstract] [Full Text]

				P. Petrossians, W. De Herder, D. Kwekkeboom, G. Lamberigts, A. Stevenaert, and A. Beckers Malignant Prolactinoma Discovered by D2 Receptor Imaging J. Clin. Endocrinol. Metab., January 1, 2000; 85(1): 398 - 401. [Full Text]

				J R Anderson, N Antoun, N Burnet, K Chatterjee, O Edwards, J D Pickard, and N Sarkies Neurology of the pituitary gland J. Neurol. Neurosurg. Psychiatry, June 1, 1999; 66(6): 703 - 721. [Full Text]

				P. L. M. Dahia and A. B. Grossman The Molecular Pathogenesis of Corticotroph Tumors Endocr. Rev., April 1, 1999; 20(2): 136 - 155. [Abstract] [Full Text]

				X. Zhang, G. A. Horwitz, A. P. Heaney, M. Nakashima, T. R. Prezant, M. D. Bronstein, and S. Melmed Pituitary Tumor Transforming Gene (PTTG) Expression in Pituitary Adenomas J. Clin. Endocrinol. Metab., February 1, 1999; 84(2): 761 - 767. [Abstract] [Full Text]

				X. Zhang, G. A. Horwitz, T. R. Prezant, A. Valentini, M. Nakashima, M. D. Bronstein, and S. Melmed Structure, Expression, and Function of Human Pituitary Tumor-Transforming Gene (PTTG) Mol. Endocrinol., January 1, 1999; 13(1): 156 - 166. [Abstract] [Full Text]

				S. L. Asa and S. Ezzat The Cytogenesis and Pathogenesis of Pituitary Adenomas Endocr. Rev., December 1, 1998; 19(6): 798 - 827. [Abstract] [Full Text]

				I. Shimon and S. Melmed Pituitary Tumor Pathogenesis J. Clin. Endocrinol. Metab., June 1, 1997; 82(6): 1675 - 1681. [Full Text] [PDF]

				D. Ray and S. Melmed Pituitary Cytokine and Growth Factor Expression and Action Endocr. Rev., April 1, 1997; 18(2): 206 - 228. [Abstract] [Full Text]

				L. Pei and S. Melmed Isolation and Characterization of a Pituitary Tumor-Transforming Gene (PTTG) Mol. Endocrinol., April 1, 1997; 11(4): 433 - 441. [Abstract] [Full Text]

				S. A. A. Abbass, S. L. Asa, and S. Ezzat Altered Expression of Fibroblast Growth Factor Receptors in Human Pituitary Adenomas J. Clin. Endocrinol. Metab., April 1, 1997; 82(4): 1160 - 1166. [Abstract] [Full Text] [PDF]